ABOS
Acumen Pharmaceuticals Steers Course Towards Breakthroughs in Alzheimer's Disease Treatment
Acumen Pharmaceuticals has made significant strides towards revolutionizing the treatment of Alzheimer's disease, as evident from its recent third-quarter 2026 conference call. The company's CEO, Dan O'Connell, and CFO, Matt Zuga, presented a detailed update on the progress made in their phase II ALTITUDE-AD